Anika Therapeutics | ANIK - Gross Profit On Sales


Anika Therapeutics reported $19.18M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Abbott USD 5.86B 675M Mar/2026
Agenus USD 34.2M 4.61M Dec/2025
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 256.46M 38.78M Mar/2026
Integra LifeSciences USD 213.21M 3.89M Mar/2026
Intrexon USD -297K 167K Jun/2024
J&J USD 17.24B 642M Mar/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Ligand Pharmaceuticals USD 48.45M 8.22M Mar/2026
MacroGenics USD 31.11M 30.14M Dec/2025
Merit Medical Systems USD 184.8M 10.56M Mar/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Smith & Nephew USD 2.09B 117M Dec/2025
Stryker USD 3.81B 675M Mar/2026
Veracyte USD 101.16M 814K Mar/2026
Xencor USD 21M 22.61M Sep/2025
Zimmer Biomet Holdings USD 1.27B 8.1M Dec/2025